The DOI matches its Crossref record.
Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis
Abstract
Objective: Methotrexate (MTX) enters cells through the reduced folate carrier (RFC‐1) and exerts part of its effects through polyglutamation to MTX polyglutamates (MTXPGs) and inhibition of 5‐aminoimidazole‐4‐carboxamide ribonucleotide transformylase (ATIC) and thymidylate synthase (TS). We investigated the contribution of common genetic polymorphisms in RFC‐1 (G80A), ATIC (C347G), and TS (28‐bp tandem repeats located in the TS enhancer region [TSER*2/*3]) and of MTXPGs to the effect of MTX in patients with rheumatoid arthritis. Methods: The study was cross‐sectional. All patients received MTX for at least 3 months. The numbers of tender and swollen joints, the Visual Analog Scale (VAS) scores for the physician's global assessment of disease activity, and the modified Health Assessment Questionnaire scores were collected. Using the VAS score for the physician's assessment of patient's response to MTX, the population of patients was dichotomized into responders to MTX (VAS score ≤2 cm) and nonresponders to MTX (VAS score >2 cm). A pharmacogenetic index was calculated as the sum of homozygous variant genotypes (RFC‐1 AA + ATIC 347GG + TSER *2/*2) carried by the patients. MTXPG concentrations were measured in red blood cells (RBCs) by high‐performance liquid chromatography. Results: The dose of MTX was not associated with the effects of MTX (P > 0.05). In contrast, increased RBC long‐chain MTXPG concentrations (median 40 nmoles/liter; range <5–131 nmoles/liter) and an increased pharmacogenetic index were associated with a lower number of tender and swollen joints (P < 0.05) and a lower score for the physician's global assessment of disease activity (P ≤ 0.001). Patients with RBC MTXPG levels of >60 nmoles/liter and carriers of a homozygous variant genotype were 14.0‐fold (95% confidence interval [95% CI] 3.6–53.8) and 3.7‐fold (95% CI 1.7–9.1), respectively, more likely to have a good response to MTX (P ≤ 0.01). Conclusion: These data suggest that measuring RBC MTXPG levels and/or the common polymorphisms in the folate–purine–pyrimidine pathway may help in monitoring MTX therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Low-Dose Methotrexate: A Mainstay in the Treatment of Rheumatoid Arthritis
Cronstein, B. N. (2005) · Pharmacological Reviews · doi:10.1124/pr.57.2.3 · Cited by 535
Chapter 1 Folate‐Mediated One‐Carbon Metabolism
Fox, J. T., & Stover, P. J. (2008) · Vitamins & Hormones · doi:10.1016/s0083-6729(08)00401-9 · Cited by 402
Koźmiński, P., Halik, P. K., Chesori, R., & Gniazdowska, E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21103483 · Cited by 326
Drug-microbiota interactions: an emerging priority for precision medicine
Zhao, Q., Chen, Y., Huang, W., Zhou, H., & Zhang, W. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01619-w · Cited by 268
Metadata
- Authors
- Dervieux, T., Furst, D., Lein, D. O., Capps, R., Smith, K., Walsh, M., & Kremer, J.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2004-09
- Volume
- 50
- Issue
- 9
- Pages
- 2766-2774
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W1983779362
- Cited by
- 337
- References
- 0
- FWCI
- 8.83
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis. https://app.cochat.ai/papers/10.1002/art.20460
- The paper
- Dervieux, T., Furst, D., Lein, D. O., Capps, R., Smith, K., Walsh, M., & Kremer, J. (2004). Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis. Arthritis & Rheumatism. https://doi.org/10.1002/art.20460
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.